Medline
MDLN
Medline (MDLN) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $43.00 from $45.00 | Oct 9, 2026 |
| UBS | Maintained | Buy | $43.00 from $45.00 | Sep 25, 2026 |
| BTIG | Maintained | Buy | $55.00 | Aug 27, 2026 |
| JP Morgan | Maintained | Overweight | $46.00 from $53.00 | Aug 12, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $34.00 from $45.00 | Aug 11, 2026 |
| Tigress Financial | Maintained | Buy | $55.00 from $62.00 | Aug 11, 2026 |
| TD Cowen | Maintained | Buy | $45.00 from $53.00 | Aug 10, 2026 |
| Stifel | Maintained | Buy | $45.00 from $50.00 | Aug 6, 2026 |
| Evercore ISI Group | Maintained | Outperform | $39.00 from $48.00 | Aug 6, 2026 |
| Truist Securities | Maintained | Buy | $47.00 from $56.00 | Aug 6, 2026 |
| RBC Capital | Maintained | Outperform | $46.00 from $53.00 | Aug 6, 2026 |
| BTIG | Maintained | Buy | $55.00 | Jul 31, 2026 |
| Baird | Maintained | Outperform | $45.00 from $57.00 | Jun 3, 2026 |
| Barclays | Maintained | Overweight | $45.00 from $50.00 | Jun 1, 2026 |
| BNP Paribas | Maintained | Neutral | $40.00 from $49.00 | May 14, 2026 |
| Tigress Financial | Maintained | Buy | $62.00 from $60.00 | May 13, 2026 |
| BTIG | Maintained | Buy | $55.00 | May 7, 2026 |
| Bernstein | Maintained | Outperform | $54.00 from $56.00 | May 7, 2026 |
| Citigroup | Maintained | Buy | $55.00 from $60.00 | May 7, 2026 |
| Citigroup | Maintained | Buy | $60.00 | Mar 11, 2026 |
Frequently asked questions
What is the latest analyst rating on MDLN?
On Oct 9, 2026, Barclays maintained Medline at Overweight with a price target of $43.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.